Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 12, 2024CancersOpen Access

Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSusan J. KimUniversity of VirginiaKCKaelyn C. CumminsUniversity of Virginia Health SystemATAllan TsungUniversity of Virginia Health System

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kim et al. (2024) studied this question.

synapsesocial.com/papers/68e6a752b6db64358762acaahttps://doi.org/10.3390/cancers16101852
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma2020 · 1,193 citations
  2. 2Sorafenib in Advanced Hepatocellular Carcinoma2008 · 13,145 citations
  3. 3Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma1994 · 130 citations
  4. 4Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.2022 · 405 citations